Author Archives: admin

Trending Now: Cancer Stem Cells (CSCs) Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026| Janssen, Qiagen, Advanced Cell…

By adminJuly 30, 2020Stem Cell Treatment

LOS ANGELES, United States: QY Research has recently published a report, titled Global Cancer Stem Cells (CSCs) Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Cancer Stem Cells (CSCs) market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Cancer Stem Cells (CSCs) market include: , Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2010378/global-cancer-stem-cells-cscs-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cancer Stem Cells (CSCs) market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cancer Stem Cells (CSCs) Market Segment By Type:

CellSearch Others

Global Cancer Stem Cells (CSCs) Market Segment By Application:

Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cancer Stem Cells (CSCs) market.

Key companies operating in the global Cancer Stem Cells (CSCs) market include , Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2010378/global-cancer-stem-cells-cscs-market

TOC

1 Cancer Stem Cells (CSCs) Market Overview 1.1 Product Overview and Scope of Cancer Stem Cells (CSCs) 1.2 Cancer Stem Cells (CSCs) Segment by Type 1.2.1 Global Cancer Stem Cells (CSCs) Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 CellSearch 1.2.3 Others 1.3 Cancer Stem Cells (CSCs) Segment by Application 1.3.1 Cancer Stem Cells (CSCs) Sales Comparison by Application: 2020 VS 2026 1.3.2 Breast Cancer Diagnosis and Treatment 1.3.3 Prostate Cancer Diagnosis and Treatment 1.3.4 Colorectal Cancer Diagnosis and Treatment 1.3.5 Lung Cancer Diagnosis and Treatment 1.3.6 Other Cancers Diagnosis and Treatment 1.4 Global Cancer Stem Cells (CSCs) Market Size Estimates and Forecasts 1.4.1 Global Cancer Stem Cells (CSCs) Revenue 2015-2026 1.4.2 Global Cancer Stem Cells (CSCs) Sales 2015-2026 1.4.3 Cancer Stem Cells (CSCs) Market Size by Region: 2020 Versus 2026 1.5 Cancer Stem Cells (CSCs) Industry 1.6 Cancer Stem Cells (CSCs) Market Trends 2 Global Cancer Stem Cells (CSCs) Market Competition by Manufacturers 2.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Manufacturers (2015-2020) 2.2 Global Cancer Stem Cells (CSCs) Revenue Share by Manufacturers (2015-2020) 2.3 Global Cancer Stem Cells (CSCs) Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Cancer Stem Cells (CSCs) Manufacturing Sites, Area Served, Product Type 2.5 Cancer Stem Cells (CSCs) Market Competitive Situation and Trends 2.5.1 Cancer Stem Cells (CSCs) Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Cancer Stem Cells (CSCs) Players (Opinion Leaders) 3 Cancer Stem Cells (CSCs) Retrospective Market Scenario by Region 3.1 Global Cancer Stem Cells (CSCs) Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Cancer Stem Cells (CSCs) Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.3.1 North America Cancer Stem Cells (CSCs) Sales by Country 3.3.2 North America Cancer Stem Cells (CSCs) Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.4.1 Europe Cancer Stem Cells (CSCs) Sales by Country 3.4.2 Europe Cancer Stem Cells (CSCs) Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Cancer Stem Cells (CSCs) Market Facts & Figures by Region 3.5.1 Asia Pacific Cancer Stem Cells (CSCs) Sales by Region 3.5.2 Asia Pacific Cancer Stem Cells (CSCs) Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.6.1 Latin America Cancer Stem Cells (CSCs) Sales by Country 3.6.2 Latin America Cancer Stem Cells (CSCs) Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.7.1 Middle East and Africa Cancer Stem Cells (CSCs) Sales by Country 3.7.2 Middle East and Africa Cancer Stem Cells (CSCs) Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Cancer Stem Cells (CSCs) Historic Market Analysis by Type 4.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Type (2015-2020) 4.2 Global Cancer Stem Cells (CSCs) Revenue Market Share by Type (2015-2020) 4.3 Global Cancer Stem Cells (CSCs) Price Market Share by Type (2015-2020) 4.4 Global Cancer Stem Cells (CSCs) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Cancer Stem Cells (CSCs) Historic Market Analysis by Application 5.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Application (2015-2020) 5.2 Global Cancer Stem Cells (CSCs) Revenue Market Share by Application (2015-2020) 5.3 Global Cancer Stem Cells (CSCs) Price by Application (2015-2020) 6 Company Profiles and Key Figures in Cancer Stem Cells (CSCs) Business 6.1 Janssen 6.1.1 Corporation Information 6.1.2 Janssen Description, Business Overview and Total Revenue 6.1.3 Janssen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Janssen Products Offered 6.1.5 Janssen Recent Development 6.2 Qiagen 6.2.1 Qiagen Corporation Information 6.2.2 Qiagen Description, Business Overview and Total Revenue 6.2.3 Qiagen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Qiagen Products Offered 6.2.5 Qiagen Recent Development 6.3 Advanced Cell Diagnostics 6.3.1 Advanced Cell Diagnostics Corporation Information 6.3.2 Advanced Cell Diagnostics Description, Business Overview and Total Revenue 6.3.3 Advanced Cell Diagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Advanced Cell Diagnostics Products Offered 6.3.5 Advanced Cell Diagnostics Recent Development 6.4 ApoCell 6.4.1 ApoCell Corporation Information 6.4.2 ApoCell Description, Business Overview and Total Revenue 6.4.3 ApoCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.4.4 ApoCell Products Offered 6.4.5 ApoCell Recent Development 6.5 Biofluidica 6.5.1 Biofluidica Corporation Information 6.5.2 Biofluidica Description, Business Overview and Total Revenue 6.5.3 Biofluidica Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Biofluidica Products Offered 6.5.5 Biofluidica Recent Development 6.6 Clearbridge Biomedics 6.6.1 Clearbridge Biomedics Corporation Information 6.6.2 Clearbridge Biomedics Description, Business Overview and Total Revenue 6.6.3 Clearbridge Biomedics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Clearbridge Biomedics Products Offered 6.6.5 Clearbridge Biomedics Recent Development 6.7 CytoTrack 6.6.1 CytoTrack Corporation Information 6.6.2 CytoTrack Description, Business Overview and Total Revenue 6.6.3 CytoTrack Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.4.4 CytoTrack Products Offered 6.7.5 CytoTrack Recent Development 6.8 Celsee 6.8.1 Celsee Corporation Information 6.8.2 Celsee Description, Business Overview and Total Revenue 6.8.3 Celsee Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Celsee Products Offered 6.8.5 Celsee Recent Development 6.9 Fluxion 6.9.1 Fluxion Corporation Information 6.9.2 Fluxion Description, Business Overview and Total Revenue 6.9.3 Fluxion Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.9.4 Fluxion Products Offered 6.9.5 Fluxion Recent Development 6.10 Gilupi 6.10.1 Gilupi Corporation Information 6.10.2 Gilupi Description, Business Overview and Total Revenue 6.10.3 Gilupi Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.10.4 Gilupi Products Offered 6.10.5 Gilupi Recent Development 6.11 Cynvenio 6.11.1 Cynvenio Corporation Information 6.11.2 Cynvenio Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.11.3 Cynvenio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.11.4 Cynvenio Products Offered 6.11.5 Cynvenio Recent Development 6.12 On-chip 6.12.1 On-chip Corporation Information 6.12.2 On-chip Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.12.3 On-chip Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.12.4 On-chip Products Offered 6.12.5 On-chip Recent Development 6.13 YZY Bio 6.13.1 YZY Bio Corporation Information 6.13.2 YZY Bio Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.13.3 YZY Bio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.13.4 YZY Bio Products Offered 6.13.5 YZY Bio Recent Development 6.14 BioView 6.14.1 BioView Corporation Information 6.14.2 BioView Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.14.3 BioView Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.14.4 BioView Products Offered 6.14.5 BioView Recent Development 6.15 Creatv MicroTech 6.15.1 Creatv MicroTech Corporation Information 6.15.2 Creatv MicroTech Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.15.3 Creatv MicroTech Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.15.4 Creatv MicroTech Products Offered 6.15.5 Creatv MicroTech Recent Development 6.16 Fluidigm 6.16.1 Fluidigm Corporation Information 6.16.2 Fluidigm Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.16.3 Fluidigm Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.16.4 Fluidigm Products Offered 6.16.5 Fluidigm Recent Development 6.17 Ikonisys 6.17.1 Ikonisys Corporation Information 6.17.2 Ikonisys Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.17.3 Ikonisys Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.17.4 Ikonisys Products Offered 6.17.5 Ikonisys Recent Development 6.18 AdnaGen 6.18.1 AdnaGen Corporation Information 6.18.2 AdnaGen Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.18.3 AdnaGen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.18.4 AdnaGen Products Offered 6.18.5 AdnaGen Recent Development 6.19 IVDiagnostics 6.19.1 IVDiagnostics Corporation Information 6.19.2 IVDiagnostics Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.19.3 IVDiagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.19.4 IVDiagnostics Products Offered 6.19.5 IVDiagnostics Recent Development 6.20 Miltenyi Biotec 6.20.1 Miltenyi Biotec Corporation Information 6.20.2 Miltenyi Biotec Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.20.3 Miltenyi Biotec Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.20.4 Miltenyi Biotec Products Offered 6.20.5 Miltenyi Biotec Recent Development 6.21 Aviva Biosciences Corporation 6.21.1 Aviva Biosciences Corporation Corporation Information 6.21.2 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.21.3 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.21.4 Aviva Biosciences Corporation Products Offered 6.21.5 Aviva Biosciences Corporation Recent Development 6.22 ScreenCell 6.22.1 ScreenCell Corporation Information 6.22.2 ScreenCell Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.22.3 ScreenCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.22.4 ScreenCell Products Offered 6.22.5 ScreenCell Recent Development 6.23 Silicon Biosystems 6.23.1 Silicon Biosystems Corporation Information 6.23.2 Silicon Biosystems Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.23.3 Silicon Biosystems Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.23.4 Silicon Biosystems Products Offered 6.23.5 Silicon Biosystems Recent Development 7 Cancer Stem Cells (CSCs) Manufacturing Cost Analysis 7.1 Cancer Stem Cells (CSCs) Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Cancer Stem Cells (CSCs) 7.4 Cancer Stem Cells (CSCs) Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Cancer Stem Cells (CSCs) Distributors List 8.3 Cancer Stem Cells (CSCs) Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast 10.1 Global Cancer Stem Cells (CSCs) Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Type (2021-2026) 10.2 Cancer Stem Cells (CSCs) Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Application (2021-2026) 10.3 Cancer Stem Cells (CSCs) Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Region (2021-2026) 10.4 North America Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.5 Europe Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.6 Asia Pacific Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.7 Latin America Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.8 Middle East and Africa Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Mesoblast sees lasting need for COVID treatment beyond a vaccine – Sydney Morning Herald

By adminJuly 30, 2020Stell Cell Research

Mesoblast is hoping its flagship product remestemcel-L will be shown to relieve acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company is running a phase 3 trial of the product in US hospitals, but the research is still in its early stages, with a pilot study of the project looking at only 12 patients.

The US Data Safety Monitoring board, which reviews clinical data, had selected a date in early September to complete an initial review of Mesoblast's phase 3 trial, the company said. There are no approved treatments for this kind of respiratory distress, and it is not yet known whether its product will prove safe and effective in a large group of patients.

Dr Itescu said the company would know the results by the end of this calendar year. If the project is successful, the product could be manufactured in Australia for export into global markets to treat COVID patients around the world.

"We're tracking pretty much as expected," Dr Itescu said.

The company has also been working on getting the same product approved in the US for use in children who have graft-vs-host disease, a complication from bone marrow transplants.

The Food and Drug Administration will review data about the effectiveness of the treatment on August 13. Dr Itescu said the regulator would advise whether the product has received approval before September 30.

Reviews of these two projects could have large implications for Mesoblast's future.

The company, which has been backed by high-profile investors including billionaire Alex Waislitz, has seen its shares turbocharged by updates on its COVID research in recent months. They jumped more than 5 per cent again on Thursday, trading at $3.84 by mid-afternoon.

The business generated $US2.1 million from customers in the June quarter and had $19.6 million in operating expenses.

Read the original post:
Mesoblast sees lasting need for COVID treatment beyond a vaccine - Sydney Morning Herald

UAE leads Covid-19 research in the Middle East – The National

By adminJuly 30, 2020Stell Cell Research

Since the onset of the coronavirus pandemic, the UAEs efforts to combat its spread and prepare for a post-lockdown reality have made it a positive example for the region and the world.

Public health officials have carried out nearly 5 million coronavirus tests over the past six months a remarkable achievement in a country with a population of 9 million. This mass-testing strategy has curbed the spread of the virus and protected the population.

Another pillar of the Emirates success thus far is the willingness to invest in local expertise and drive resources towards Covid-19 research. In May, QuantLase Imaging Lab, which is part of International Holdings Company in Abu Dhabi, announced it had developed a rapid-testing technology capable of diagnosing coronavirus in mere minutes.

The Covid-19 screenings use a diffractive phase interferometry (DPI) test, which can detect early signs of the body fighting a virus. A centre has been set up on the border between Dubai and Abu Dhabi to facilitate travel into the latter, where a negative coronavirus test remains a requirement for entry.

The facility carries out thousands of tests a day, with more DPI screening centres set to open soon.

Abu Dhabi and Al Ain are also the first cities in the world to commence Phase III trials for a World Health Organisation-enlisted coronavirus vaccine. More than 10,000 people have volunteered for the final-stage trials, which aim to identify antibodies that provide immunity against the virus. Only three out of 20 coronavirus vaccines are currently in Phase III trials globally.

While the world awaits a successful vaccine, the Emirates is developing new treatments locally. In May, Abu Dhabi Stem Cell Centre announced it had produced a stem cell therapy treatment that helps to alleviate Covid-19 symptoms. The centre has thus far treated 2,000 patients free of charge.

This week, a one-month study of coronavirus immunity was launched in Abu Dhabi. The tests used will detect whether a person has been infected with coronavirus in the past, providing scientists with data on how widespread infections have been, as well as the prevalence of asymptomatic carriers. Such results will be instrumental in designing future public health policies.

The ground-breaking developments have been made easier by the fact that the UAE was already heavily focused on becoming a leading centre for medical research in general. Now, it is facilitating advancement in other areas of medicine, demonstrating the synergies that can form when developing a global medical hub.

The UAEs experience thus far provides an important lesson for public policymaking

This week, Abdullah Nazir Ahmad Muhammad became the first patient in the UAE to undergo bone-marrow transplant, in Sheikh Khalifa Medical City, Abu Dhabi. The transplant used stem cell technology originally developed to treat Covid-19 infections, and as a result the blood-cancer patient was given a second chance of life.

The UAEs experience thus far provides an important lesson for public policymaking: that tackling challenges as daunting as a viral pandemic takes long-term planning and investment in strategic sectors. The same qualities are required in order to deal with a pandemics aftermath.

Ghadan 21, a set of large-scale reforms and projects launched last year by Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, has helped to diversify the economy and develop non-oil sectors. Early investment in education to foster local talent has long attracted the brightest minds from around the world. When the pandemic struck, the country already had a solid healthcare infrastructure.

Next year marks the 50th anniversary of the UAEs founding. Seen through the larger lens of human history, five decades is a very short period of time. But as the UAEs pandemic experience shows, no matter how far back a nations history stretches, it must make use of the time it has to prepare for a brighter future.

Updated: July 29, 2020 05:41 PM

Here is the original post:
UAE leads Covid-19 research in the Middle East - The National

Demand for Cryopreservation Equipment Market to Experience a Significant Dip in 2020, Influenced by COVID-19 Pandemic 2020-2029 | Thermo Fisher…

By adminJuly 30, 2020Stell Cell Research

The recently published market study by MarketResearch.Biz highlights the current and future trends that are expected to influence the dynamics of the Cryopreservation Equipment Marketin the upcoming years. The report introspects the supply chain, cost structure, and recent developments pertaining to the Cryopreservation Equipment market in the report. Further, the micro and macro-economic factors that are likely to impact the growth of the Cryopreservation Equipment market are thoroughly studied in the presented market study.

Cryopreservation Equipment market report offers a detailed dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, and ongoing improvements in both historic and present contexts.

The Renowned Players- Thermo Fisher Scientific Inc, Chart Biomedical Co Ltd, Custom Biogenic Systems, Barber-Nichols Inc, Merck KGaA, Linde LLC., Praxair Technology Inc, Cryologic Pty. Ltd, Planer PLC, Charter Medicals, Nikkiso Cryo Inc

To Obtain All-Inclusive Information On Forecast Analysis Of Global Cryopreservation Equipment Market, Request A Free Pdf Sample Report Here:https://marketresearch.biz/report/cryopreservation-equipment-market/request-sample

Cryopreservation Equipment study is a perfect blend of qualitative and quantifiable information highlighting key market developments, industry, absolute opportunity assessment and competitors challenges in gap analysis and may be trending in the Cryopreservation Equipment market. The strategies followed by leading Cryopreservation Equipment market players which can reflect growth during the forecast period 2020-2029 is analyzed during this report. The past market development, opportunities, and market risks are covered during this study. the elemental Cryopreservation Equipment Market overview, development scope, market dynamics, growth challenges, and influencing factors are briefed.

Click Here To Download (Short Term & Long Term) Impact Analysis [PDF] : To Know What Is The Impact Of COVID 19 On Cryopreservation Equipment Market And How Market Will Grow In The Upcoming Period 2020-2029?

Segmentation Assessment-

The presented study ponders over the numerous segmentation of the Cryopreservation Equipment and offers a fair assessment of the supply-demand ratio of each segment.

Global cryopreservation equipment market segmentation, by equipment type:

Freezers Cryopreservation Freezers Drystore Freezers Incubators Sample Preparation Systems Accessories Freezer Box Cryogenic Vaporizer Cryopreservation Vials Others Global cryopreservation equipment market segmentation, by cryogen:

Liquid Nitrogen Oxygen Liquid Helium Argon Global cryopreservation equipment market segmentation, by application:

Cord Blood Stem Cells Sperms, Semen, and Testicular Tissues Embryos & Oocytes Others Global cryopreservation equipment market segmentation, by end user:

Stem Cell Banks Biotechnology and Pharmaceutical Organizations Stem Cell Research Laboratories Others

The regional section of this Cryopreservation Equipment market report covers the investigation of various parameters such as production volume, revenue, export-import figures, profit margin, and local consumption in different regional markets. Regions that have been covered for this market:

1. North America (United States, Canada)

2. Europe (Germany, Spain, France, UK, Russia, and Italy)

3. Asia-Pacific (China, Japan, India, Australia, and South Korea)

4. Latin America (Brazil, Mexico, etc.)

5. The Middle East and Africa (GCC and South Africa)

In this study, the years considered to estimate the market size of the Cryopreservation Equipment are as follows:

Base Year: 2019 | Estimated Year: 2020 | Forecast Year: 2020 to 2029

Key Offerings of the Cryopreservation Equipment Industry Report

> Growth Drivers and Opportunities: Comprehensive investigation on growth-driving factors and opportunities for market players in different regional markets

>Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for 10-year period.

>Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis

>Regional Market Forecast: Thorough examination of each regional market to arm stakeholders with necessary information to take critical decisions

>Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Cryopreservation Equipment market

Any Query? Fill Free To Inquire Here. Well Put You On The Right Path:https://marketresearch.biz/report/cryopreservation-equipment-market/#inquiry

Table Of Contents :

Executive Summary

Market Overview

Market Landscape

Market ecosystem

Value chain analysis

Market Sizing

Market definition

Market segment analysis

Market size 2020

Market outlook: Forecast for 2020-2029

Porters Five Forces Analysis

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

Market Segmentation

equipment type, cryogen, application, end user, and region

Customer landscape

Overview

Geographic Landscape

Geographic segmentation

Geographic comparison

Europe Market size and forecast 2020-2029

North America Market size and forecast 2020-2029

APAC Market size and forecast 2020-2029

South America Market size and forecast 2020-2029

MEA Market size and forecast 2020-2029

Key leading countries

Market opportunity by geography

Drivers, Challenges, and Trends

Market drivers

Volume driver Demand led growth

Volume driver Supply led growth

Volume driver External factors

Volume driver Demand shift in adjacent markets

Price driver Inflation

Price driver Shift from lower to higher-priced units

Market challenges

Market trends

Vendor Landscape

Overview

Landscape disruption

Vendor Analysis

Thermo Fisher Scientific, Inc. Chart Biomedical Co. Ltd. Custom Biogenic Systems Barber-Nichols Inc. Merck KGaA Linde LLC. Praxair Technology, Inc. Cryologic Pty. Ltd. Planer PLC Charter Medicals Nikkiso Cryo Inc.

Appendix

Scope of the report

Currency conversion rates for US$

Research methodology

List of abbreviations

....For Detailed InformationClick Here For Complete TOC

We are very grateful to you for reading our report. If you would like to find more details about the report or want to customize it, please contact us. If you have any specific requirements, please let us know and we will provide you with the report as you wish.

Motivations to Trust Our Business Insights

> Proven track history of delivering high-quality and insightful market studies

>Data gathered from credible sources including product managers, marketing executives, sales representatives and more

>Providing accurate insights for over ten industrial verticals

>Swift delivery of customized reports without any delays

>Up-to-date statistical surveying and analytical tools used to curate market reports

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:

Mr. Benni Johnson (

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:

Visit link:
Demand for Cryopreservation Equipment Market to Experience a Significant Dip in 2020, Influenced by COVID-19 Pandemic 2020-2029 | Thermo Fisher...

Plant Stem Cell Market Size, Share, Trends Analysis and Growth Forecast by Type and Application from 2020-2026 – Bulletin Line

By adminJuly 30, 2020Stell Cell Research

Global Coronavirus pandemic has impacted all industries across the globe,Plant Stem Cell Marketis no exception. As the global economy heads towards major recession post-2009 crisis, Coherent Market Insights has published a recent study that meticulously studies the impact of this crisis on the GlobalPlant Stem Cell Market and suggests possible measures to curtail them.

The research report of the Plant Stem Cell Market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Plant Stem Cell Market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Plant Stem Cell Market growth opportunities in the industry.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/98

Manufacturers are facing continued downward pressure on demand, production and revenues as the COVID-19 pandemic strengthens .manufacturers should be prepared for major global supply chain disruptions. Thus, some of the key players are mainly focusing on research & development to provide innovative products to the client. The report provides in-depth analysis regarding key players of the market along with their company profiles that contain all the information of its happening and recent developments. Various factors influencing the market development and growth as well as the latest development strategies implemented by key players that can influence the growth of the market is explained.Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

The global Plant Stem Cell Market can be segmented into various types and applications. All the type and application segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Moreover, the study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest-growing type segment for Plant Stem Cell Market.

Take Note that: The Covid-19 situation and its impacts are studied by our analysts in such a way that the recovery state post-COVID-19 of the market is explained which shows the lucrative rate for the manufacturers and producers. And also, other information related to Covid-19 like consumer behavior, impact on industry & market, latest strategies that can benefit the market players is explained in the report.

The Plant Stem Cell Market research report contains an executive summary, market introduction & analysis, industry analysis, key-players & their in-depth information, raw-materials and various other parameters. All the data is provided in theory as well as with help of graphical representations like graphs, tables, charts, etc as this can make it easy for a decision-maker to understand the information briefly & in an easier manner. The global level opportunities and position of the market along with the challenges are explained in-depth in the report. The report showcases data form the base year 2020 till the forecast year 2027 along with the revenue and compound annual growth rate. The report also provides historical data for the year 2015 to 2019.

Market by Region:

Advantages of purchasing the Plant Stem Cell Market report:

Coherent Market Researchreport provides all the necessary information from the introduction to a conclusion by covering every aspect, scenario and latest development of the market. Hence it provides entrepreneurs, decision-makers to strengthen their firms, start-up companies and other influencers of a company to improvise and implement the factors mention in the report. Some of the crucial factors that are of interest to the companies have been specifically identified & studied. For instance, market segmentation, revenue, Covid-19 impact, forecast analysis, major players, regional analysis, product types & applications, new innovation strategies & product introduction and various other factors have been regarding the growth of the market have been mentioned. Hence this report can serve as an informative blueprint for a business.

Customization of the report available: According to the needs of the buyer we customize the parts that are essential for your business. Connect with us to know more and to get all the information regarding the research report based on what suits you.

It highlights the specific region that holds higher revenue as compared to the other regions and explains the reason responsible for this upper hand of a particular region.

The Plant Stem Cell research report also covers various drivers of the market, opportunities & restraints. It also provides information related to the overall market by evaluating various elements to provide the SWOT & PESTEL analysis. Overall information covering all the factors, aspects, scenarios& situations of the market on a global standard has been mentioned in the research report.

The objective of the Plant Stem Cell Market Report:

To Provide strategic profiles of major players in the Plant Stem Cell market, analyzing their fundamental capacities, and drawing a competitive scenario for the market. To provide insights about factors that cause market growth. To analyze the Plant Stem Cell Market based on various factors- price analysis, supply chain analysis, porter five force analysis, etc. To provide a detailed analysis of the Plant Stem Cell market structure along with the forecast. To Provide a country-level analysis of the current market size and prospects. To Provide a country-level analysis for the segment through applications, product types, and sub-segments by region.

Key Reasons to Purchase:

To gain insightful analyses of the market and have a comprehensive understanding of the Global Plant Stem Cell Market Industry Analysis and Forecast 2019-2025 and its commercial landscape Learn about the market strategies that are being adopted by your competitors and leading organizations. To understand the future outlook and prospects for Plant Stem Cell Market industry analysis and forecast 20192025.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [emailprotected]

Read the original post:
Plant Stem Cell Market Size, Share, Trends Analysis and Growth Forecast by Type and Application from 2020-2026 - Bulletin Line

Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. – Red…

By adminJuly 30, 2020Adult Stem Cells

Global Stem Cell Reconstructive Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal. However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide. Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologous o Bone Marrow o Adipose Tissue o Blood Syngeneic Other Global Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem Cell Global Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn Other Global Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute Others Global Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA) Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @ https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Website:www.maximizemarketresearch.com

View post:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - Red...

Shady Stem Cell Therapies Can Cause tumours, Infections …

By adminJuly 30, 2020Stem Cell Doctors

A team of neurologists are raising a red flag over risky and unproven stem cell therapies. Their new study suggests that their fellow doctors are frequently asked about these controversial procedures by desperate patients. Many doctors are also seeing patients with serious complications from stem cell therapy, including seizures, infections, and spinal tumours.

Stem cells are the raw material that our body uses to replace other damaged or ageing cells. Scientists have been hopeful about the potential to use these cells as a way to surpass the bodys natural regenerative ability and treat currently incurable diseases, including degenerative neurological disorders like multiple sclerosis.

But so far, there are only a few proven uses in medicine for stem cells, such as bone marrow transplants to treat certain blood cancers. Most of the evidence for their claimed benefits elsewhere is either limited or entirely lacking. These caveats havent stopped the consumer stem cell industry from growing, though, with clinics offering treatments on an experimental basis, often without express approval from the Food and Drug Administration.

This new study, published Wednesday in the Annals of Neurology, was a survey of over 200 neurologists across the country, including a third who specialise in multiple sclerosis. Among other questions, the neurologists were asked if they had ever come across patients who had used or wanted to use stem cells to treat their health problems. For those with patients previously given stem cells, they were also asked about any health complications they had seen that were possibly linked to stem cell treatment.

Almost 90% of the neurologists surveyed said they had been asked by a patient or a close family member about stem cells, a rate that was slightly higher for those with patients who had incurable conditions like multiple sclerosis. Many of those conversations involved patients asking for the neurologists blessing to go ahead with stem cell therapy. But only 28% of the doctors reported feeling completely prepared to talk to their patients about the topic.

One of the studys points is that these discussions are happening in more than 90% of every outpatient neurology clinic, but many of the doctors are not ready, said senior author Jamie Imitola, a neuroscientist at the University of Connecticut who specialises in multiple sclerosis and stem cell research. And if theyre not fully prepared, then thats shocking, because these are the doctors that should be up to date.

Two-thirds of neurologists also said they had treated someone who had already gotten a stem cell therapy, while 25% of respondents said they had come across a patient with complications thought to be related to a stem cell therapy. Some of the specific complications listed have been reported before, but Imitola said the percentage of doctors who reported any at all is much higher than you would expect from the small number of case reports available. It suggests that side-effects linked to these procedures may be more common than previously thought.

Ive had doctors call us and tell us that patients dont want to report problems with their stem cell treatment, he added. They feel embarrassed, number one, because they have a complication or two, because they feel they were ripped off.

The long list of complications reported by doctors in the survey included stroke, paralysis, bloodborne infections like hepatitis C, and several deaths. In two cases, doctors reported the emergence of a tumour along the spinal cord; in one case, the tumour had cells that didnt seem to belong to the patient, suggesting the donors cells had somehow turned cancerous. In other cases, the therapy seemed to worsen the progression of the disease it was meant to treat. Still other patients had spent tens of thousands of dollars on their treatment, with no lasting improvement.

The surveys findings are limited, especially when it comes to the reported complications, since theyre reliant on the recollection of doctors rather than medical records or other verified information. But the study points to all sorts of systemic problems, Imitola said. Many of these patients are understandably looking for a miracle, and theres a growing mistrust of science in general, he noted. That makes the wondrous claims peddled by many clinics selling stem cell therapy look all the more appealing. And it makes the relationship between a doctor and their patient all the more important to get right.

There is a sense around the country that scientists are hiding new therapies for this or that. That we dont want people to get stem cell therapy, because there is some ulterior motive, he said. The reality is that for us to translate stem cells into something real, its going to require a great deal of work. Because, ultimately, we want to provide people the best therapy, the best opportunities.

To help neurologists be more prepared to talk about stem cells, the researchers have created a patient-friendly handout based on their findings, translated into 17languages. Imitola has also set up a patient registry where doctors and patients can anonymously report any possible complications linked to stem cell therapy.

Read the original post:
Shady Stem Cell Therapies Can Cause tumours, Infections ...

Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults – PsychCentral.com

By adminJuly 29, 2020Stem Cell Medical Center

A new Israeli study finds that a new hyperbaric oxygen therapy protocol can improve cognitive function in older adults.

The main areas of improvement were attention, information processing speed, and executive function, in addition to global cognitive function. All of these typically decline with age, according to researchers at the Shamir Medical Center and the Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University in Israel.

The researchers report there was also a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The randomized controlled clinical trial included 63 healthy adults with an average age of 64. According to the researchers, 33 underwent HBOT for three months, while the remaining 30 were the control group.

Cognitive function was measured by a standardized comprehensive battery of computerized cognitive assessments before and after the three months. Cerebral blood flow (CBF) was evaluated by a magnetic resonance imaging technique for brain perfusion.

Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal aging population, said co-author Dr. Shai Efrati, head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center. In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration.

Years of research led to an advanced understanding of HBOTs ability to restore brain function, added co-author Dr. Amir Hadanny of the Sagol Center.

Efrati and Hadanny designed the study based on a hyperbaric oxygen therapy (HBOT) protocol developed at the Sagol Center over the past 10 years.

In the past, we have demonstrated HBOTs potential to improve/treat brain injuries such as stroke, traumatic brain injury, and anoxic brain injury due to sustained lack of oxygen supply by increasing brain blood flow and metabolism, Hadanny said. This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms.

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body, the researchers explained. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds, the researchers noted.

There is a growing body of evidence on the regenerative effects of HBOT, they add. The researchers demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment) leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. These targeted genes induce stem cell proliferation, reduce inflammation, and induce the generation of new blood vessels and tissue repair mechanisms, according to the researchers.

The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population, Efrati said.

We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research.

The study was published in the peer-reviewed journal Aging.

Source: American Friends of Tel Aviv

APA Reference Wood, J. (2020). Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults. Psych Central. Retrieved on July 29, 2020, from https://psychcentral.com/news/2020/07/27/hyperbaric-oxygen-therapy-can-enhance-cognition-in-healthy-older-adults/158208.html

Read the rest here:
Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults - PsychCentral.com

Induced Pluripotent Stem Cells Market | 2020 Global …

By adminJuly 29, 2020Induced Pluripotent Stem Cells

The MarketWatch News Department was not involved in the creation of this content.

Jul 29, 2020 (The Expresswire) -- Induced Pluripotent Stem Cells Market2020 Global Industry Trends, Size, Share Analysis Report. According to this report Global Induced Pluripotent Stem Cells Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2026. Induced Pluripotent Stem Cells Market includes comprehensive information derived from depth study on Induced Pluripotent Stem Cells Industry historical and forecast market data. Global Induced Pluripotent Stem Cells Market Size To Expand moderately as the new developments in Induced Pluripotent Stem Cells and Impact of COVID19 over the forecast period 2020 to 2026.

Induced Pluripotent Stem Cells Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Induced Pluripotent Stem Cells Market report is helpful for strategists, marketers and senior management, And Key Players in Induced Pluripotent Stem Cells Industry.

Get Sample Report To Know How COVID-19 Impacting Induced Pluripotent Stem Cells Market

Global Induced Pluripotent Stem Cells Market Insights:

Report Analyzes Global Induced Pluripotent Stem Cells Market Growth Size, Share And Trends By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education and research institutes, Biotechnological companies) and Geography Forecast till 2026.

Key Players Analyzed In Report: Astellas Pharma, Ncardia, Applied StemCell, FUJIFILM Cellular Dynamics, Axol Bioscience, Bristol-Myers Squibb Company,RandD Systems, Fate Therapeutics, Evotec AG, ViaCyte Inc.

Active government support for RandD activities through research grants is driving the global induced pluripotent stem cells. Increasing private funding and rising shift towards regenerative medicines are predicted to favor induced pluripotent stem cells revenue. Further, induced pluripotent stem cells have created new avenues in clinical research, regenerative medicines, and disease modeling. This has also paved the way to numerous mergers and acquisitions and potential pipeline products and patents. In addition, the diversity of donor candidates is a factor predicted to aid induced pluripotent stem cells growth. Moreover, increasing accessibility towards the cell of origin is also expected to boost the global induced pluripotent stem cells market in the forthcoming year. However, ethical issues related to the donors and potential risk of tumors are factors predicted to hamper the growth of the global induced pluripotent stem cells.

STEMCELL Technologies Inc., a global biotechnology company launched mTeSR Plus, an enhanced version of mTeSR1, a widely published feeder-free human pluripotent stem cell (hPSC) maintenance medium. mTeSR Plus will be used to prevent onset acidosis. The launch of mTeSR Plus is likely to encourage global induced pluripotent stem cells growth owing to the design of the mTeSR Plus, which offers more consistent cell culture environment through sustained medium pH and stabilized components including FGF2. Furthermore, warning by FDA for marketing dangerous unapproved stem cells products is expected to alert pharmaceutical companies to market FDA approved products. This factor will, in turn, enable growth of the global induced pluripotent stem cells. For instance, the U.S Food and Drug Administration (FDA) sent a warning to Genetech, Inc. for marketing stem cell therapy without the U.S FDA approval and nonconformity of Good Manufacturing Practice (CGMP).

Regional Market Overview:

Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2024, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

Geographically, the global induced pluripotent stem cells market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is expected to dominate the global induced pluripotent stem cells market during the forecast period due to the increasing RandD investment by key players for potential pipeline products. In Europe, the global induced pluripotent stem cells market is anticipated to grow significantly during the forecast period. The active government support and product launches are predicted to favor growth in the region. For instance, in 2018, Ncardia, a company working for drug discovery using stem cell, launched Xpress.4U LightPace Cor.4U, a kit for improving and simplifying the use of optical pacing of cardiomyocytes, a human induced pluripotent stem cell. The aforementioned factors together are enabling growth in Europe.

Intended Audience:

Competitive Analysis:

The Induced Pluripotent Stem Cells Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included this report with Porter's five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Report Highlights:

In-depth information about the latest Induced Pluripotent Stem Cells Industry trends, opportunities, and challenges.

Extensive analysis of the growth drivers And barriers.

Competitive landscape consisting of investments, agreements, contracts, novel product launches, strategic collaborations, and mergers and acquisitions.

List of the segments and the niche areas.

Comprehensive details about the strategies that are being adopted by key players.

Table of Content:

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4.1. Prevalence of Key Indications, 2017 (Key Countries)

4.2. Economic (Key Countries)

4.3. Key Mergers and Acquisitions

4.4. Pricing Analysis, Key Players, 2017

4.5. Overview: New Developments in Induced Pluripotent Stem Cells

5.1. Key Findings / Summary

Continue...

David Karli Launches New Treatment for Patients with severe Arthritic Conditions – THISDAY Newspapers

By adminJuly 29, 2020Stem Cell Clinic

Colorado-based doctor, David Karli, has announced the launch of a new bone marrow-derived stem cell injection program for patients with arthritic conditions and both acute and chronic soft tissue disorders of muscle, tendon and ligament.

The Elizabethtown College graduate is a former Chief Resident of the Harvard Medical School Department of Physical Medicine & Rehabilitation and runs a fitness programme for enterpreneurs with hectic schedules.

Dr Karlis avid interest in regenerative medicine and the development of non-surgical interventions for a variety of conditions has led to the development of Platelet Rich Plasma (PRP, Platelet Gel) and Bone Marrow Stem Cell injection therapy programs for patients with acute and chronic musculoskeletal injuries.

His work with The Steadman Clinic has lead to pioneering work in developing safe and effective use of biologics in orthopaedic medicine for both surgical and non-surgical applications.

A Diplomate of the American Board of Physical Medicine and Rehabilitation, Dr. Karli also maintains active membership in multiple professional societies. He was a recent co-investigator in the first Level I randomized, double-blind, placebo-controlled clinical trial researching the efficacy of PRP in chronic tennis elbow, a landmark study slated for publication in the American Journal of Sports Medicine.

View original post here:
David Karli Launches New Treatment for Patients with severe Arthritic Conditions - THISDAY Newspapers